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Introduction: In recent years, intermittent preventive treatment for pregnancy (IPTp) with 
sulfadoxine-pyrimethamine (SP) has become policy in much of sub-Saharan Africa. But resis-
tance to SP has been spreading across sub-Saharan Africa and thus the effectiveness of IPTp-SP 
has been questioned. The present study therefore sought to assess the incidence of placental 
malaria, low birth weight, and anemia of two IPTp-SP approaches (directly observed treatment 
scheme versus no directly observed treatment) in Anonkoua-Kouté and Samo, Côte d’Ivoire 
where the reported prevalence of dfr single mutant 108 was 62% and 52.2%, respectively.
Methods: The study was a longitudinal design involving pregnant women and was conducted 
in Anonkoua-Kouté, a suburban area, and Samo, a rural area, from January 2008 through 
March 2009. Women of a pregnancy less than 28 weeks duration were randomized to receive 
SP (1.5 g/0.075 g SP) in a single intake twice and were followed up monthly until delivery. 
Doses were administered under supervision in the controlled IPTp group, while SP was given 
free to women in the uncontrolled IPTp group with a recommendation to take it at home. The 
primary end point was the proportion of low birth weight infants (body weight , 2500 g) and the 
secondary end point was the rate of severe anemia and placental malaria detected at delivery.
Results: A total of 420 pregnant women were enrolled (212 and 208, respectively, in the con-
trolled and uncontrolled groups). Delivery outcome was available for 378 women. In the modi-
fied intention-to-treat analysis, low birth weight infants were born from 15.5% of women of the 
uncontrolled IPTp group and from 11.9% of women in the controlled IPTp group (P = 0.31). 
The per-protocol population analysis showed consistent results. The proportion of women with 
placental malaria infection, moderate anemia (hemoglobin , 11 g/dL), and severe anemia 
(hemoglobin , 8 g/dL) at delivery were similar between the two groups (P . 0.05).
Conclusion: The study showed that the two approaches were equivalent, suggesting that unsu-
pervised IPTp-SP free of charge should be used in areas where implementation of the directly 
observed treatment scheme suffers from many constraints.
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Introduction
In sub-Saharan Africa, approximately 25 million pregnant women are at risk of 
  Plasmodium falciparum infection every year. In recent years, intermittent preventive 
treatment for pregnancy (IPTp) with sulfadoxine-pyrimethamine (SP) has become 
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policy in much of sub-Saharan Africa.1 IPTp consists of 
administration of a curative dose of an efficacious anti-
malarial drug at least twice during the second and third 
trimesters of pregnancy during routinely scheduled ante-
natal clinic visits irrespective of the presence of signs for 
a malaria infection.2 Currently, IPTp-SP has been rated as 
having the most favorable cost–benefit profile because of its 
relatively low cost, high compliance, and efficacy in reducing 
maternal anemia and low birth weight (LBW).3,4 However, 
implementation of IPTp in most settings is limited by social, 
cultural, economic and operational challenges despite good 
coverage of antenatal services.5,6 In addition, a controversy 
has raised questions as to whether this was the most appro-
priate approach for malaria prevention in African pregnant 
women given the reported increase in parasite resistance 
to SP in some areas.4,7–9 Recent studies have shown high 
prevalence of dhfr and dhps resistant mutant parasites in 
the authors’ study sites (unpublished data).10,11 The current 
national treatment guidelines and policy for malaria in Côte 
d’Ivoire adopted the World Health Organization’s recommen-
dation for malaria prevention and control during pregnancy. 
This means the implementation of an intervention package 
into the antenatal care (ANC) services including the use of 
insecticide-treated nets (ITNs) and IPTp as well as effective 
case management of malaria infection in pregnant women 
and anemia.1 Thus, since 2005, the National Malaria Control 
Program recommends SP as the first-line agent for IPTp and 
quinine for treatment of clinical malaria in all   trimesters. 
Since this adoption, few studies have investigated the effi-
cacy of IPTp-SP.8 Compliance with the recommendation 
that the IPTp drug should be given under supervision in the 
clinic was very low.12,13 Studies related to IPTp use during 
pregnancy in Côte d’Ivoire are limited and few were found 
to have looked into compliance especially with the directly 
observed treatment (DOT) scheme. In a study conducted in 
2006 in four maternities, placental parasitemia was identified 
in 29.26% of delivering women who received two or more 
doses of SP.14 This ineffectiveness of IPTp could be related 
to the inefficacy of SP as the IPTp drug or participants did 
not take SP as the intake was not supervised in most par-
ticipants. These findings were confirmed by Vanga-Bosson 
et al.15 The low use of IPTp-DOT scheme and poor adherence 
in previous studies may be a proxy to the practice of IPTp 
in the whole country.
The objective of this study was to assess the incidence of 
placental malaria, LBW, and maternal anemia of two IPTp-SP 
approaches (controlled or DOT scheme versus uncontrolled 
IPTp-SP or no DOT). Results obtained from this study will 
allow for implementation of effective and knowledge-based 
intervention against this major cause of maternal and child 
morbidity and mortality in sub-Saharan Africa.
Methods
Study sites
The trial was conducted from January 2008 through March 
2009 in Anonkoua-Kouté and Samo. Anonkoua-Kouté is 
a suburban area of Abidjan while Samo is a village near 
Bonoua and located 50 km north of Abidjan. In the study 
sites, perennial malaria transmission with seasonal peaks is 
mostly attributable to P . falciparum.
Ethical clearance
The study was approved by the National Ethics   Committee 
of Life and Health Sciences of Côte d’Ivoire. All study 
participants were informed in their local language about the 
study objectives and procedures. For each study participant, 
written informed consent was obtained and the participant 
was free to withdraw consent at any time of the study without 
influencing their access to health services.
Enrollment
An identification number was given to each potentially 
eligible woman who attended the antenatal clinic and a first 
questionnaire was completed to assess eligibility.
Eligibility criteria were: at least 15 years old, living in the 
study area or the surrounding regions for at least 6 months, 
availability for follow-up during the pregnancy and willing-
ness to deliver at the study site, a pregnancy of less than 
28 weeks duration, willingness to come back for a planned 
visit and be visited by a field worker during pregnancy, and 
willingness to comply with study procedures.
Women who reported living 10 km from the site, who 
were severely ill (had medical conditions requiring hospital 
admission), or who reported prior adverse drug reaction 
to sulfa-containing medications or any other antimalarial 
medication were excluded.
For each study participant, a Case Report Form at inclu-
sion was completed, which provided information on age, 
district of residence, sociodemographic characteristics, 
education, previous and current obstetric history, previous 
illness, treatment during the current pregnancy, and measures 
for malaria prevention. Gestational age was estimated using 
the date of the last menstrual period and/or by measurement 
of uterine fundal height. Obstetrical ultrasound was also used 
to determine the gestational age. Venous blood samples were 
collected for determination of the hemoglobin (Hb) level, 
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and thick and thin blood smears were performed to detect 
malaria. Human immunodeficiency virus (HIV) screening 
was routinely undertaken in the study area after informed 
consent. Women who were known to be HIV infected before 
enrollment were also recruited.
Randomization and treatment
Study participants were randomly assigned to one of the two 
treatment groups using a computer generated random list. The 
study pharmacist, who did not take part in any other activi-
ties in the study, prepared an individual randomization code 
envelope from the randomization list. The sealed envelopes 
were sequentially numbered. When an eligible woman joined 
the study, the envelope with the lowest available number 
was opened, revealing the assignment of the participant to 
the appropriate treatment group.
In the controlled IPTp group, all women received DOT 
while in the uncontrolled IPTp group the treatment admin-
istration was not supervised (no DOT). Each woman in the 
no DOT group was given medication for self administration 
at home. Efforts were made in this group to sensitize each 
participant regarding the importance in taking the drugs to 
avoid the consequences of malaria for herself and her baby. 
The empty sachets were verified by a field worker as evidence 
of taking the drug 72 hours after.
In the two groups, the IPTp regimen consisted of a 
single curative dose of 1.5 g/0.075 g SP at each of the ANC 
visits (ANC1 and ANC2). Doses were given twice from the 
second trimester, at least 1 month apart. Regardless of their 
gestational age, all women at recruitment received a long 
lasting ITN (LLITN).
Follow-up
Enrolled pregnant women were followed up to delivery. At 
enrollment and subsequent visits, the study midwife collected 
the study data using a standardized questionnaire.
A physical examination was performed to measure 
axillary temperature, blood pressure, weight, and uterine 
height.
ANC visits
At each ANC visit, information on previous illnesses and 
treatments were collected and fundal height and axillary 
temperature were measured. The number of tablets of SP-
DOT and other medicines handed to mothers were recorded. 
A blood sample was obtained by fingerprick for thick and 
thin blood films. Similar information was collected at 
unscheduled visits.
Delivery
During labor, venous blood samples were collected for 
determination of Hb concentration and malaria diagnosis. 
  Immediately after delivery, babies were weighed using 
a hanging weighing scale (Model 180; Salter Brecknell, 
West Midlands, United Kingdom). Data regarding newborn 
characteristics (vital status at birth, birth weight, sex, and the 
presence of twins or malformation) were collected. Blood 
smears were made with blood collected from the maternal 
side of the delivered placenta and the umbilical vein cord. 
In addition, pieces of placental tissues were used to prepare 
impression smears after swabbing it on blotting paper. 
If women delivered outside and attended the study site 
  immediately, Hb level, sex, Apgar index, and birth weight 
were assessed.
Sample size calculation
An absolute difference of 15% in the prevalence of placental 
malaria between the uncontrolled and controlled groups was 
considered to be of interest. It has been reported that about 
29% of placental malaria occurs in the study sites;14 and the 
sample size calculation for a 5% type I error and a 10% type 
II error yielded 169 subjects in each group. For practical 
reasons, it was finally decided to include 400 participants 
(200 in each group).
Laboratory procedures
All participants received routine prenatal tests which included 
blood group and antibody screening, rubella, toxoplasma, 
syphilis, and midstream urine test, Hb electrophoresis, blood 
urea nitrogen, glycemia, and creatinemia screening, and 
obstetrical ultrasound.
Thick films and placental impression smears were stained 
with 10% Giemsa for 15 minutes. To determine the percent-
age of malaria parasitemia from placental impression smears, 
malaria parasite-infected red cells were counted against 2000 
erythrocytes.
Placental infection status was categorized as infected 
(presence of any asexual parasite stages in the placenta) 
and noninfected (parasite negative smear). Smears with 
malaria pigment but with no asexual parasite stages were 
declared as unknown and were not included in the analysis. 
Microscopic examination of blood smears was done under oil 
immersion for parasite detection and 200 high-power fields 
were examined before the smear was considered negative. 
Parasites were enumerated using thick film, as previously 
described.16 The parasite density (per 1 µL of blood) was 
calculated, assuming a normal leukocyte level of 8000/1 µL. 
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The thin film was used to speciate the parasites. Each blood 
film was independently examined by two microscopists. In 
cases of discrepancy, a third microscopist counted the num-
ber of parasites in the films. The average of two counts that 
agreed was used as the final level of parasitemia.
Venous blood (5 mL) was collected using butterfly nee-
dles into ethylenediaminetetraacetic acid Vacutainer® tubes 
(BD Diagnostics, Franklin Lakes, NJ) for measurement of 
Hb levels using an automated hematology analyzer (Mythic 
22; Orphee SA, Geneva, Switzerland).
Management of anemia and malaria cases
Study participants found to be anemic at ANC visits (Hb 
level ,11 g/dL) were treated, based on national guidelines, 
with ferrous sulfate (200 mg) and folic acid (0.25 mg) given 
as a single combined tablet daily for 30 days. Confirmed cases 
of malaria (axillary temperature $ 37.5°C and with a positive 
smear test) were given treatment with quinine, based on the 
national malaria treatment guidelines for pregnant women.
Definitions
LBW was defined as a birth weight less than 2500 g, prema-
turity as a gestational age of less than 37 weeks (determined 
by Ballard examination), and maternal anemia as moderate to 
severe for Hb ,11 g/dL and Hb ,8 g/dL, respectively.
Statistical analysis
The primary efficacy endpoint was the proportion of LBW 
infants. The secondary end points were the proportions of 
women with placental malaria (ie, presence of asexual-stage 
parasites in the placental impression smear), moderate mater-
nal anemia (Hb ,11 g/dL), and severe maternal anemia 
(Hb ,8 g/dL) at delivery as well as the mean birth weight 
and mean maternal Hb level at delivery. For the primary end 
point, the analysis was performed on the modified intention-
to-treat (ITT) population of women who completed the study 
(and for the women whose infants’ information on birth 
weight was collected). The analysis was also conducted for 
the per-protocol (PP) population, excluding women who were 
lost to follow-up. For secondary endpoints, the analyses were 
performed in the PP population and they included data on 
stillbirths and spontaneous abortion. Differences in frequen-
cies were compared by either chi-squared or Fisher’s exact 
tests as appropriate, and continuous variables by Student’s 
t-test when the data were normally distributed.   Nonparametric 
tests were used for nonnormally distributed data. In the mul-
tivariable analysis, the factors associated with the dependant 
variable (LBW or placental malaria or anemia) based on 
univariable analysis were included. Statistical analyses were 
performed using Stata® version 10.0 (StataCorp LP, College 
Station, TX).
Results
Characteristics of the study participants 
at enrollment
Study population
A total of 628 pregnant women were screened. Overall, 
420 women were randomized to receive IPTp-SP (212 in 
controlled IPTp group and 208 in uncontrolled IPTp group). 
The reasons for ineligibility were unwillingness to consent 
to the study (no permission from husband), gestational 
age more than 28 weeks, low probability of completing 
follow-up (planning to travel before delivery), and allergies 
to sulfonamides.
Endpoint was reached in 366 and 339 women for modified 
ITT and PP analysis, respectively, for both treatment groups. 
The trial profile is shown in Figure 1.
Characteristics of the mothers are summarized in Table 1. 
The mean age of the participants was 25.86 and 26.13 years 
in the uncontrolled and controlled groups, respectively. 
Primigravidae and secundigravidae represent 50.2% of the 
total sample size. There was more secundigravidae in the 
uncontrolled group than the controlled group (31.3% versus 
21.7%; P = 0.02).
Follow-up
The second dose was not administered to 12% of women in the 
controlled group and 11% of women in the uncontrolled group. 
The main reasons for failure to administer the second dose (con-
trolled versus uncontrolled) included travel (5% versus 2%), 
refusal because of the occurrence of an adverse event after the 
first dose (2% versus 3%), and delivery before administration 
of the second dose (1% versus 2%) (Figure 1). Overall, 25 (6%) 
of 420 women (nine in controlled group and 16 in uncontrolled 
group) delivered outside the study maternity clinics. For those 
women, birth weights were recorded from ANC cards. A total 
of 366 birth weights were collected (including weights for 
stillborn babies). The mean birth weight was 2898.13 ± 37.39 g 
and 2967 ± 33.52 g in the uncontrolled and controlled groups, 
respectively, regarding the modified ITT population. There 
was no significant difference between the two groups for the 
mean birth weight or the rate of LBW (P = 0.31). In the PP 
population, the mean weight was 2894 ± 38.15 g (uncontrolled 
group) and 2966.70 ± 35.47 g (controlled group) (P = 0.16). In 
the modified ITT analysis, LBW infants were born to 15% of 
women in the uncontrolled IPTp group and to 12% of women in 
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the controlled IPTp group (P = 0.31). The PP analysis showed 
consistent results (Table 2). The factors associated with LBW 
in the multivariable analysis were placental malaria (adjusted 
odds ratio = 6.9, 95% confidence interval 2.6–18), maternal 
malaria at delivery (odds ratio = 0.6, 95% confidence interval 
0.08–3.9), and moderate anemia (odds ratio = 1.7, 95% confi-
dence interval 0.8–3.5) (Table 3).
By stratifying according to gravidity, there was no sig-
nificant difference between groups in terms of LBW either 
in primigravidae, secundigravidae, or in multigravidae, but 
Women screened (n = 628)
Women eligible (n = 438) 
Did not have husband’s 
permission (n = 15)
Gestational age >28 
weeks (n = 86)  
Overall women randomized (n = 420)
Assigned uncontrolled IPTp arm (n = 208)   Assigned controlled IPTp arm (n = 212) 
Received full two doses (n = 184)  Received full two doses (n = 187)
Lost at follow-up (n = 20) 
Moved to another area (n = 15)
Lost at follow-up (n = 22) 
Moved to another area (n = 20)
Refusals (n = 18)
Delivery outcomes
(n = 190; 177 live births) 
Delivery outcomes
(n = 188; 175 live births) 
Deliveries before 
appointment (n = 3)
Lost at follow-up (n = 1)
Travels (n = 10) 
Deliveries before 
appointment (n = 4) 
Lost at follow-up (n = 4)
Refusals (n = 6) 
Placental impression smears
analyzed (n = 174) 
Placental impression smears
analyzed (n = 165)   
Placental malaria (n = 7) Placental malaria (n = 12)
Birth weights collected (n = 185) Birth weights collected (n = 181)
Figure 1 Trial profile.
Abbreviation: IPTp, intermittent preventive treatment during pregnancy.
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sample sizes had a low power to detect a difference between 
groups (Table 2).
All women who were parasitemic at enrollment received 
antimalarial treatment using quinine. All patients recovered 
completely and were microscopically confirmed   negative. 
The rate of malaria at inclusion was 9.6% and 8.5% in the 
uncontrolled and controlled group, respectively.   During 
the follow-up period, 18 (8.7%) and eleven (5.2%) clini-
cal episodes of P . falciparum malaria were observed in 
the uncontrolled and controlled groups, respectively 
(Table 4). Most of the clinical episodes occurred in the 
second trimester. The proportion of women with peripheral 
malaria at delivery was 4.9% in the uncontrolled group and 
Table 1 Sociodemographic characteristics at inclusion
Uncontrolled IPTp group (N = 208) Controlled IPTp group (N = 212) P value
n % 95% CI n % 95% CI
Age
15–19 years 29 13.9 0.09–0.19 25 11.8 0.76–0.16 0.49
20–29 years 126 60.6 0.54–0.68 119 56.1 0.49–0.63 0.32
30–39 years 50 24 0.18–0.30 66 31.1 0.25–0.37 0.11
40–50 years 3 0.5 -0.003–0.023 2 1 -0.003–0.023 0.68
Gravidity
Primigravid 43 20.7 0.15–0.27 57 26.9 0.21–0.33 0.13
Secundigravid 65 31.3 0.25–0.37 46 21.7 0.16–0.28 0.02
Multigravid 100 48 0.41–0.55 109 51.4 0.44–0.55 0.49
Gestational age
9–15 weeks 44 21.2 0.15–0.27 28 13.2 0.08–0.18 0.032
16–20 weeks 97 46.6 0.40–0.54 108 50.9 0.44–0.58 0.35
21–25 weeks 48 23.1 0.17–0.29 60 28.3 0.22–0.34 0.21
26–30 weeks 19 9.1 0.51–0.29 16 7.5 0.04–0.12 0.56
Education
None 129 62 0.55–0.69 88 41.5 0.34–0.48 ,0.0001
Primary school 57 27.4 0.21–0.33 56 26.4 0.20–0.32 0.82
Secondary school 15 7.2 0.04–0.10 41 19.3 0.14–0.24 0.0002
University 7 3.4 0.00–0.05 27 12.7 0.08–0.18 0.0004
Profession
homemaker 128 61.5 0.54–0.68 108 50.9 0.44–0.58 0.028
Shopkeeper 55 26.4 0.20–0.32 56 26.4 0.20–0.32 1
Student 4 1.9 0.00–0.04 10 54.7 0.02–0.08 0.18
Couturier 6 2.9 0.01–0.05 17 8 0.04–0.12 0.02
Teacher 4 1.9 0.00–0.04 1 0.5 -0.00–0.01 0.021
Student (university) 5 2.4 0.00–0.04 12 5.7 0.03–0.09 0.09
hairdresser 1 0.5 -0.00–0.01 4 1.9 0.00–0.04 0.37
Others 5 2.4 0.00–0.04 4 1.9 0.00–0.04 0.74
Sickle cell status
Positive 2 1 -0.00–0.02 3 1.4 -0.00–0.02 1
Negative 61 29.3 0.23–0.35 86 40.6 0.34–0.48 0.015
Unknown 145 69.7 0.64–0.76 123 58 0.51–0.65 0.012
HIV status
Positive 5 2.4 0.00–0.04 7 3.3 0.00–0.05 0.57
Negative 125 60.1 0.53–0.67 115 54.2 0.47–0.61 0.22
Unknown 78 37.5 0.31–0.45 90 42.5 0.36–0.50 0.30
Notes: Data are number (%) of women with the characteristic, unless otherwise indicated. P values were determined by chi-squared or Fisher’s exact test as appropriate. 
P , 0.05 was considered statistically significant.
Abbreviations: CI, confidence interval; hIV, human immunodeficiency virus; IPTp, intermittent preventive treatment during pregnancy.
4% in the controlled group (PP analysis). There were no 
significant differences in the prevalence of placental infec-
tion (impression smear positive) between the two groups 
(7.3% versus 4%; P = 0.19) (Table 5). Women with clinical 
malaria during pregnancy had a high risk (odds ratio = 7.9) 
of placental malaria.
At inclusion, 65 (31.3%) and 56 (26.4%) participants 
had moderate anemia (Hb ,11 g/dL) in the uncontrolled 
and controlled groups, respectively. The mean Hb concentra-
tion at delivery was 9.87 ± 0.1419 g/dL in the uncontrolled 
group and 10.22 ± 0.1301 g/dL in the controlled group. In 
the uncontrolled and controlled groups, the rate of moderate 
anemia (Hb ,11 g/dL) was 50.9% and 46%, respectively, 
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Table 2 Proportion of women with low birth weight infants (,2500 g)
Women assessed Uncontrolled IPTp group Controlled IPTp group P value
n/N % 95% CI n/N % 95% CI
All
ITT 55/208 26.4 0.20–0.32 49/212 23.1 0.17–0.29 0.43
Modified ITT 28/181 15.5 0.10–0.20 22/185 11.9 0.07–0.17 0.31
PP 26/165 15.8 0.10–0.22 20/174 11.5 0.06–0.16 0.25
Primigravid
ITT 14/59 23.7 0.13–0.35 14/68 20.6 0.11–0.31 0.67
Modified ITT 9/54 16.7 0.07–0.27 6/54 11.1 0.03–0.19 0.38
PP 9/51 17.7 0.07–0.29 6/57 10.5 0.02–0.18 0.29
Secundigravid
ITT 20/65 30.8 0.20–0.42 10/42 23.8 0,11–0.37 0.43
Modified ITT 9/54 16.7 0.07–0.27 4/36 11.1 0,01–0.21 0.55
PP 8/51 15.7 0.06–0.27 3/33 9.1 -0,00–0.20 0.51
Multigravid
ITT 21/84 25 0.16–0.34 25/102 24.5 0.16–0.32 0.92
Modified ITT 10/72 13.9 0.06–0.22 12/89 13.5 0.06–0.20 0.92
PP 9/63 14.3 0.05–0.23 11/84 13.1 0.06–0.20 0.84
Notes: Data represent number of births for which low birth weight was detected/number of singleton births analyzed (% of births for which low birth weight was detected). 
P values were determined by chi-squared or Fisher’s exact test as appropriate. P , 0.05 was considered statistically significant.
Abbreviations: CI, confidence interval; IPTp, intermittent preventive treatment during pregnancy; ITT, intention-to-treat analysis; PP, per-protocol analysis.
Table 3 Factors associated with low birth weight or placental 
malaria: logistic regression model
Odds ratio 95% CI P value
Low birth weight
Placental malaria 8.5 1.8–40.2 0.007
Malaria infection (at delivery) 0.6 0.1–4 0.59
Moderate anemia (hb ,11 g/dL) 1.7 0.8–3.5 0.14
Severe anemia (hb ,8 g/dL) 1 0.3–3.4 1
Placental malaria
Primigravid 5.3 0.5–60 0.18
Secundigravid 1.9 0.2–20.7 0.61
Malaria during pregnancy 6.8 1–44.4 0.04
Moderate anemia 4.2 0.5–38.8 0.20
Note: Adjusted odds ratio of placental malaria and malaria during pregnancy was 
6.9 and 7.4, respectively.
Abbreviations: CI, confidence interval; hb, hemoglobin.
while the proportion of severe anemia (Hb ,8 g/dL) was 
14.6% and 9.8%, respectively (Table 5).
Pregnancy outcome
Information on pregnancy outcome and on the survival 
of babies born from women enrolled in this study is sum-
marized in Table 6. Delivery was observed in 188 and 190 
women, respectively, in the uncontrolled and controlled 
groups (Figure 1).
Adverse events: mothers
Moderate adverse events occurred in 24% and 22% of the 
participants, respectively, in the controlled and uncon-
trolled groups. The most common complaints were nausea, 
vomiting, tiredness, and headaches; and no significant 
d  ifference between the two groups was observed (P . 0.05) 
(Figure 2).
Discussion
Currently, the World Health Organization recommends, for 
prevention of malaria during pregnancy, a package of inter-
ventions for pregnant women living in areas where malaria is 
endemic, including IPT, ITNs, case management of clinical 
malaria, and diagnosis and treatment of anemia.1 Clinical 
trials have demonstrated the positive impact of IPTp-SP or 
other effective antimalarials, such as mefloquine, on placental 
parasitemia, anemia, and LBW.17,18 In recent years, IPTp-SP 
has been the cornerstone of malaria control in pregnant 
women living in stable transmission areas.
The comparison of efficacy (mainly on birth weight) 
between pregnant women receiving IPTp-SP, either under 
supervision or without any control, in Côte d’Ivoire was 
assessed in this study. Birth weight was used as the primary 
end point, because it is a good public health indicator of the 
consequences of malaria in pregnancy, and it correlated with 
the efficacy of IPTp in several studies.18,19
Maternal anemia has been proposed as an indicator for 
monitoring malaria control in sub-Saharan Africa,20 based 
on the excess of risk of anemia in primigravidae compared 
to multigravidae.
The prevalence of malaria infection during pregnancy 
was lower in the controlled group than in the uncontrolled 
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group with no statistical difference. The results showed that 
the presence of malaria parasites in the peripheral blood of 
clinically symptomatic pregnant women is an indication of 
ongoing placental infection, as previously shown.21 Other 
studies have shown that peripheral parasitemia at any stage 
of the pregnancy was significantly correlated with placental 
infection at delivery.22,23 Additionally, studies have indicated 
that peripheral and placental parasitemia decrease with 
increasing parity among pregnant women.24,25 It has been 
observed that pregnant women, especially primigravidae and 
secundigravidae, are more susceptible to malaria infections.22 
Although there is increasing evidence that prevalence of 
malaria infections is parity-related and primigravidae women 
are more susceptible to malaria than multigravidae women, 
this study did not show any association between malaria 
infection and parity. This finding may have been caused 
by the failure of a small sample size and the presence of 
LLITNs to show any association between parity or gravidity 
and malaria infection.
It is important to note that women with microscopically 
detectable placental P . falciparum malaria had a higher risk 
of delivering an LBW baby than those without detectable 
placental P . falciparum corresponding to a relative risk of 
6.9, supporting the strong association between P . falciparum 
Table 4 Rates of parasitemia, reported fever, and anemia among participants
Uncontrolled IPTp group Controlled IPTp group P value
n/N (%) Mean Median 95% CI n/N (%) Mean Median 95% CI
Fever (T $37.5°C)
At inclusion 40/208 (19.2) 37.7 37.5 13.7–24.3 14/212 (6.6) 37.7 37.7 2.8–9.2 0.0001
During pregnancy 25/208 (12) 38.0 37.9 7.6–16.4 17/212 (8) 38.1 37.9 4.3–11.7 0.17
At delivery 24/192 (12.5) 37.8 37.7 8.2–17.8 18/188 (9.6) 37.6 37.5 5.7–14.3 0.36
Parasitemia
At inclusion 20/208 (9.6) 150.1 0 5.9–14.1 18/212 (8.5) 47 0 4.3–1.7 0.68
During pregnancy 18/208 (8.7) 456 0 5.1–12.9 11/212 (5.2) 317.7 0 2.1–7.9 0.16
At delivery 10/186 (5.3) 1345.6 0 02.0–8.5 7/186 (3.7) 332.3 0 0.9–6.4 0.45
Anemia at inclusion
(hb ,11 g/dL) 65/208 (31.3) 9.8 10 24.7–37.3 56/212 (26.4) 10.2 10.5 20.1–31.9 0.27
Notes: P values were determined by chi-squared or Fisher’s exact test as appropriate. P , 0.05 was considered statistically significant.
Abbreviations: CI, confidence interval; hb, hemoglobin; IPTp, intermittent preventive treatment during pregnancy; T, temperature.
Table 5 Comparative efficacy of uncontrolled and controlled intermittent preventive treatment during pregnancy: secondary end 
points in crude analysis
Finding by analysis Uncontrolled IPTp group Controlld IPTp group P value
n/N % 95% CI n/N % 95% CI
Placental malariaa
ITT 55/208 26.4 0.20–0.32 45/212 21.2 0.16–0.26 0.21
PP 12/165 7.3 0.03–0.11 7/174 4 0.01–0.07 0.19
Maternal peripheral malaria at delivery
ITT 32/208 15.3 10.4–20.1 33/212 15.5 10.6–20.3 0.95
PP 10/186 5.3 02.0–08.5 07/186 3.7 00.9–06.4 0.45
Moderate anemiab at delivery
Primigravid 26/51 51 0.37–0.69 29/57 50.9 0.38–0.64 1
Secundigravid 28/52 53.9 0.40–0.68 13/33 39.4 0.22–0.56 0.19
Multigravid 30/62 48.4 0.36–0.60 38/84 45.2 0.44–0.66 0.71
Total 84/165 50.9 0.41–0.57 80/174 46 0.39–0.53 0.37
Severe anemiac at delivery
Primigravid 9/51 17.7 0.07–0.29 6/57 10.5 0.03–0.19 0.29
Secundigravid 9/52 17.3 0.07–0.27 3/33 9.1 -1.68–1.86 0.35
Multigravid 6/62 9.7 0.03–0.17 8/84 9.5 -1.67–1.87 0.92
Total 24/165 14.6 0.10–0.20 17/174 9.8 -1.67–1.87 0.18
Notes: aDefined as the presence of asexual-stage parasites in the placental impression; bdenoted by a hemoglobin level of ,11 g/dL; cdenoted by a hemoglobin level of ,8 g/dL. 
Data represent number of deliveries for which placental malaria, anemia, or severe anemia was detected/number of deliveries analyzed (% of deliveries for which placental malaria, 
anemia, or severe anemia was detected). P values were determined by chi-squared or Fisher’s exact test as appropriate. P , 0.05 was considered statistically significant.
Abbreviations: CI, confidence interval; IPTp, intermittent preventive treatment during pregnancy; ITT, intention-to-treat analysis (missing data included); PP, per-protocol 
analysis.
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malaria and the risk of LBW.24 There was no difference 
in terms of LBW between the two groups, although more 
pregnant women with malaria episodes were seen in the 
uncontrolled group.
The results showed no statistically significant difference 
between the controlled and uncontrolled groups regarding the 
prevalence of LBW and anemia at delivery. The results are 
consistent with efficacy results reported from several sub-
Saharan African countries17,18,26–28 in regard to the prevalence 
of LBW and severe anemia in the controlled IPTp group.
In contrast, results from Gambia show a lower preva-
lence of LBW compared to the present study.29 The lack 
of difference between the two groups in the prevalence of 
LBW and severe anemia could be explained by the fact that 
SP was provided to the women in the uncontrolled group 
with a recommendation to take the drug at home. However, 
it has been demonstrated that a highly efficacious interven-
tion given under strict trial conditions rarely translates into 
an equally effective intervention when implemented under 
programmatic conditions.30–32 There are many factors that 
have the potential to influence the relative implementability of 
interventions including: the complexity of the interventions,33 
the capacity of the health system and health providers to 
deliver the interventions at the scale required, and the accept-
ability of the interventions to providers and users.
During the study, SP was not always available at phar-
macy sites and clean cups and water were also not available 
to administer the drugs. The women should buy their drugs 
at an external pharmacy and take the drugs at home. Regular 
availability of SP in the health facility is an important factor 
in improving the use of IPTp and implementation of the DOT 
scheme.12,13 SP for IPTp in public hospitals in Côte d’Ivoire 
was supplied by the Ministry of Health. However, periodic 
supply shortages were frequently reported. The other main 
constraints to practicing DOT were lack of clean water and 
cups at ANC clinics.12 Good quality services at ANC clinics 
Table 6 Pregnancy outcomes
Finding by analysis Uncontrolled IPTp Group Controlled IPTp Group P value
n/N % 95% CI n/N % 95% CI
Premature deliverya
ITT 26/208 12.5 0.08–0.16 30/212 14.2 0.09–0.19 0.61
PP 5/165 3 0.00–0.06 8/174 4.6 0.02–0.08 0.45
Spontaneous abortionb
ITT 27/208 13 0.08–0.18 27/212 12.7 0.08–0.18 0.92
PP 7/165 4.2 0.01–0.17 5/174 2.9 0.00–0.06 0.49
Stillbirthc
ITT 33/208 15.9 0.11–0.21 35/212 16.5 0.11–0.21 0.86
PP 6/165 3.6 0.01–0.07 8/174 4.6 0.02– 0.08 0.65
Notes: aDefined as birth at less than 37 weeks’ gestation, according to the Ballard score; bdefined as the expulsion of a fetus before 28 weeks’ gestation; cdefined as the delivery 
of a dead child after 28 weeks’ gestation. P values were determined by chi-squared or Fisher’s exact test as appropriate. P , 0.05 was considered statistically significant. 
Abbreviations: CI, confidence interval; IPTp, intermittent preventive treatment during pregnancy; ITT, intention-to-treat analysis; PP, per-protocol analysis.
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Figure 2 Proportion and type of adverse event. The most common complaints were nausea, vomiting, tiredness, and headache. There was no significant difference between 
the two groups (P . 0.05). P values were determined by chi-square or Fisher’s exact test as appropriate.
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are necessary to promote high coverage and to achieve actual 
and perceived health benefits for mothers and their children. 
Allowing pregnant women to take the IPTp drug unsuper-
vised, either at the clinic or at home, makes compliance 
uncertain and undermines the essence of IPTp.
HIV infection is known to be associated with an increased 
risk of malaria and LBW, and it may have affected the occur-
rence of LBW and maternal anemia.34 HIV may have acted 
as a confounder in the present study. In the clinical trial sites, 
HIV screening was routinely undertaken by the National 
HIV Control Program during the trial, but the HIV status was 
only determined for 60% of the women. However, the overall 
prevalence of HIV infection in the present study area was 
4%.35 Even though bed nets are not traditionally used in this 
area, the delivery of LLITN through ANC was well accepted 
and compliance with their use was very high according to the 
questionnaire taken at enrollment. These results cannot be 
attributed to IPTp-SP alone as ITNs appeared to be an important 
variable in determining the efficacy of IPTp. Some studies on 
the combined use of ITNs and IPTp demonstrated the evidence 
of effectiveness of these interventions when used in combina-
tion.36,37 It is possible that if an effective ITN is used regularly, 
IPTp may not be required in some populations.38 Although 
SP is generally considered to be a safe drug when used for 
IPTp, it can rarely cause serious skin reactions and hemato-
logical side effects.39 No serious adverse events attributable 
to the administration of SP were seen in this study for which 
the proportion of women who reported an adverse event was 
24% and 22% in the controlled and uncontrolled groups.
The present study was a small, regional prospective 
study and therefore had certain limitations, namely, the small 
sample size and lack of a control group. Larger studies are 
needed to compare the two approaches with a control arm in 
the context of high resistance to SP in the country.
In conclusion, the two approaches were equivalent sug-
gesting that unsupervised IPTp-SP free of charge should 
be used in areas where implementation of the DOT scheme 
suffers from many constraints. Encouragement of respectful 
communication between midwives and their patients can help 
to reinforce the trust relationship that exists.
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